Clinical impact of ATR checkpoint signalling failure in humans.
O'Driscoll
Mark
M
Genome Damage and Stability Centre, University of Sussex, Brighton, East Sussex BN1 9RQ, UK.
Jeggo
Penny A
PA
D000818:Animals; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism; D004249:DNA Damage / Q000235:genetics*; D005057:Eukaryotic Cells / Q000378:metabolism*; D018507:Gene Expression Regulation, Developmental / Q000235:genetics; D018816:Genes, cdc / Q000502:physiology*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D009421:Nervous System Malformations / Q000235:genetics; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*
D018797:Cell Cycle Proteins; C576597:ATR protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases